Imaging providers should still administer gadolinium-based contrast agents (GBCAs) when necessary, according to a recent commentary published in the Journal of the American College of Radiology. However, the authors added, assessing the “necessity, benefits and risks” of each examination and minimizing repeated scans on the same patient is recommended.